Skip to main content

LIVE

OverviewAnalystsInstitutionalElite HoldersEarningsNews
PCVX

Vaxcyte, Inc.

PCVX

NASDAQ·Healthcare·Biotechnology·Mkt cap $8.6B

$59.84

▼ -2.16%

P/E

-7.83

Mkt Cap

$8.6B

52-Wk Range

$30.32–$65.00

52-Week Range

$30.32 - $65.00

P/E

-7.83

Fwd P/E

-7.29

Beta

1.21

Div Yield

0.00%

Avg Vol

1.4M

Shares Out

143.9M

Mkt Cap

$8.6B

Price action

Price chart

Up 94.3% over the trailing year

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

3 reasons

  • Novel 24-valent pneumococcal vaccine design with broader serotype coverage than existing competitors
  • Proprietary protein conjugate vaccine platform technology enabling rapid development across multiple bacterial pathogens
  • First-mover advantage in addressing antibiotic-resistant strains and emerging pneumococcal variants
▼

Bear Case

1 risk

  • Average volatility.

Growth

Stable outlook

VAX-24 Phase 1/2 clinical trial progression and potential regulatory approvals

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Strong

+16.4% over 3m

Quality

Loss-making

Mixed fundamentals

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Nov 3, 2026

“
Q3 26 RECAP

AUG 5, 2026

Reported EPS of -$1.97 vs -$2.06 consensus (+4.4% surprise).

EPS beat +4.4%

EPS surprise · last 4Q

1 of 1 beats

Estimate

Actual

Q3 26

+4.4%

Revenue trend · last 8Q

—

—

—

—

—

—

—

—

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

Q2 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

View full earnings history →

Wall Street consensus

Analyst coverage

Live ratings and price targets aggregated across covering analysts.

View full analyst page →

vs Industry

How PCVX stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.